iiinova — where your digital self keeps evolving

Dominique Guerrot @dguerrot.bsky.social · 31/05/2026

Important metaanalysis presented at #ESH2026 & in The Lancet: In patients with CKD, each 5 mmHg reduction in systolic BP reduced major cardiovascular events by ~9%, with similar relative benefits across CKD stages, proteinuria status and baseline BP levels. linkinghub.elsevier.com/retrieve/pii...

093 0

Dominique Guerrot @dguerrot.bsky.social · 08/03/2026

Great to see the fantastic nephrology podcast community highlighted by #NephMadness 👍 French-speaking listeners may also enjoy #NephrOdio, a nephrology education podcast with 630K downloads to date !

054 0

Dominique Guerrot @dguerrot.bsky.social · 24/08/2025

#NephrOdio podcasts 🎧 🚀 Half a million downloads !

https://open.spotify.com/show/2UBeBVbxnfv8F9S82GENGa?si=JHcAmscnTPq3c25152duxw

162 0

Dominique Guerrot @dguerrot.bsky.social · 06/08/2025

💊 First-line treatment: RAAS blockade (#ACEi or #ARB). Other drugs can be added depending on context: • thiazide(-like) diuretics • calcium channel blockers • β-blockers → Adapted based on comorbidities, side effects, or tolvaptan use.

110 0

Dominique Guerrot @dguerrot.bsky.social · 06/08/2025

📚 The 2025 #KDIGO Guidelines recommend ambitious BP targets to manage hypertension in ADPKD: 🎯 ≤110/75 mmHg (HBPM) for adults <50 y with preserved renal function (G1–G2), 🎯 <120 mmHg systolic (office BP) in older adults, if tolerated.

121 0

Dominique Guerrot @dguerrot.bsky.social · 06/08/2025

🔬 Before kidney function declines, 2 disease-specific mechanisms drive early #hypertension in #ADPKD: 📍 Local ischemia due to kidney #cyst expansion → RAAS activation 📍 Loss of polycystin function in blood vessels → primary #endothelial dysfunction → This sets ADPKD apart from other forms of CKD

100 0

Dominique Guerrot @dguerrot.bsky.social · 06/08/2025

🫀 #Hypertension in autosomal dominant polycystic kidney disease: unique pathways, common consequences. In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease. Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵

184 0

Dominique Guerrot @dguerrot.bsky.social · 12/04/2025

Mmmmh, curious to see where ESH2023 recommends SBP<120

340 0

Dominique Guerrot @dguerrot.bsky.social · 09/04/2025

Just published in NDT : #SGLT2i for patients with #ADPKD – closing the evidence gap With experts from 🇩🇪🇳🇱🇯🇵🇺🇸🇫🇷 we review: ✅ Rationale for SGLT2i in ADPKD ✅ Preclinical and observational evidence ✅ Potential disease-specific benefits and risks ✅ Ongoing/upcoming trials, incl. #DAPAPKD & #STOPPKD

https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaf061/8108808

194 0

Dominique Guerrot @dguerrot.bsky.social · 25/03/2025

Thanks Swapnil! Here is the link to the #NephrOdio podcast evaluated in the study: open.spotify.com/show/2UBeBVb...

001 0

Dominique Guerrot @dguerrot.bsky.social · 04/03/2025

📍Pourquoi développe-t-on une #HTA ? 🫀 Vasoconstriction, rigidité vasculaire, hypervolémie, inflammation… L’HTA résulte généralement de plusieurs mécanismes intriqués 🔄 🎙️ Dans ce nouvel épisode de #NephrOdio, on vous décrypte ça en 6 min chrono ! 📢 Écoutez ici 👉 open.spotify.com/episode/7CpB...

052 0

Dominique Guerrot @dguerrot.bsky.social · 18/01/2025

Hi Swapnil, as you may know 2 large RCTs, DAPA-PKD & STOP-PKD have secured academic funding to evaluate the use of SGLT2i in ADPKD. They are set to launch in 2026. Upon completion, both trials will combine their datasets in a pooled analysis, called FLOZIN-PKD. Hope you like the name 😉

0208 0

Dominique Guerrot @dguerrot.bsky.social · 13/01/2025

🎙️ L’enregistrement de la saison 3 de #NephrOdio, dédiée à la #physiologie rénale, est en cours ! Après les saisons 1 (Items EDN) et 2 (ECOS), les #podcasts du #CUEN continuent sur leur dynamique ! 🚀 📅 Disponible en mars 2025 sur toutes les plateformes

141 0

Dominique Guerrot @dguerrot.bsky.social · 21/11/2024

🤔 Should most older people with BP 120–139 / 70–89 mmHg be treated, as suggested by #ESC 2024 #hypertension guideline ? Interesting counterpoint here : www.tandfonline.com/doi/full/10....

131 0

Dominique Guerrot @dguerrot.bsky.social · 16/11/2024

Here are the main results of the #BROAD RCT. Composite primary outcome (stroke, MI, treatment or hospitalization for HF, or CV death) ✅ Kidney outcomes ❌ (as usual in BP trials) #AHA24

286 0